CTI upgrades to new releases of remote data entry and adverse event reporting products from Oracle
CTI Clinical Trial and Consulting Supports Growing Business with Expanded Oracle Clinical Footprint
Use of Oracle® Remote Data Capture Enables More Agile Reporting to Regulatory Organizations
Redwood Shores, CA – November 3, 2008
News Facts
· CTI<http://www.ctifacts.com/> Clinical Trial and Consulting Services (CTI)<http://www.ctifacts.com/> is upgrading and expanding its use of Oracle applications for clinical development to support the company’s continued growth in the U.S. and global markets.
· CTI, a specialty drug and market development company based in Cincinnati, Ohio, has recently upgraded to the newest releases of Oracle® Clinical<http://www.oracle.com/industries/life_sciences/oracle-clinical-data-sheet.pdf> and Oracle Adverse Event Reporting System<http://www.oracle.com/industries/life_sciences/aers45_datasheet.pdf>.
· The company is also upgrading to Oracle Remote Data Capture 4.5.3<http://www.oracle.com/industries/life_sciences/rdc-onsite-datasheet.pdf>, Oracle’s electronic data capture (EDC) solution, to leverage new functionality designed to meet the needs of trial sponsors and investigative site personnel, including the product’s zero-client footprint that enables improved global access.
· The growing company, which serves more than 50 biotech and pharmaceutical organizations globally is expanding its Oracle footprint with the deployment of Oracle Clinical Trial Management System<http://www.oracle.com/applications/crm/siebel/resources/siebel-lifescience-clinical-trial-management-system-data-sheet.pdf>, moving from a system developed in house to a best-of-breed solution that provides greater scalability and flexibility in managing all aspects of clinical study planning, preparation, performance and reporting.
· The company focuses on developing therapies targeting very ill patients. The clinical trial process for such drugs often requires more frequent, extensive and rapid reporting to a trial’s Data Safety Monitoring Board (DSMB), an independent body responsible for assessing a study and its risk.
· With Oracle Clinical and Oracle Remote Data Capture, CTI can quickly deliver data to a DSMB or regulatory agencies, such as the U.S. Food and Drug Administration (FDA), without the need to key in information from paper case report forms (CRFs) – a process that is time consuming and presents opportunities for data entry error.
· CTI conducts approximately 60 percent of its trials using EDC technology.
· The 10-year old company invested in industry-leading Oracle Clinical applications at its inception to help credential it in the market.
Making the Grade: Registries as Sources of Regulatory-Grade Real-World Evidence (RWE)
February 13th 2025Peter Wahl, PhD, VP of Global Scientific Affairs at CorEvitas, discusses the critical role of protocol-driven registries in generating regulatory-grade RWE for safety, effectiveness, and regulatory decision-making. He covers key considerations for selecting the right type of registry, the advantages over EMR datasets, and how registries fulfill FDA and EMA post-marketing safety requirements.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.